An interventional study of Transcranial Alternating Current Stimulation (tACS) in Generalized Anxiety Disorder (GAD) and Chronic Insomnia, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label pilot clinical trial to evaluate the effects of transcranial alternating current stimulation (tACS) in adults diagnosed with generalized anxiety disorder (GAD) and chronic primary insomnia. The study will involve 30 participants who will receive 20 sessions of tACS over four weeks. The stimulation will be delivered at 15 mA and 77.5 Hz using the Nexalin device. The main goal is to assess improvements in anxiety and sleep quality. Results from this study will provide preliminary evidence for future randomized controlled trials.
Generalized Anxiety Disorder (GAD) and chronic primary insomnia are highly prevalent and frequently co-occurring psychiatric conditions associated with significant functional impairment and reduced quality of life. Both disorders are characterized by dysregulation of cortical and subcortical neural circuits involved in emotional regulation and sleep-wake control, including abnormal oscillatory activity in fronto-limbic networks. Although pharmacological and psychotherapeutic interventions are considered first-line treatments, a substantial proportion of patients remain symptomatic or experience adverse effects, highlighting the need for novel neuromodulatory strategies.
Transcranial alternating current stimulation (tACS) is a non-invasive brain stimulation technique that delivers low-intensity sinusoidal electrical currents at specific frequencies to entrain endogenous neural oscillations. By modulating frequency-specific cortical rhythms, tACS may influence neural synchrony and connectivity patterns implicated in anxiety and sleep disturbances.
The present study is an open-label, single-arm pilot clinical trial designed to investigate the feasibility, safety, tolerability, and preliminary clinical effects of tACS in adults with GAD and chronic insomnia. Participants will undergo 20 stimulation sessions administered over four consecutive weeks (five sessions per week). Stimulation will be delivered using the Nexalin device at a frequency of 77.5 Hz and an intensity of 15 mA. Electrodes will be positioned over the frontal pole (Fpz) and bilateral mastoid regions according to the international 10-20 EEG system.
Clinical assessments will be conducted at baseline, at the end of the 4-week treatment phase, and at a 4-week post-treatment follow-up visit. The study will examine changes in anxiety severity, sleep quality, mood symptoms, global clinical status, and cognitive/functional performance to characterize the potential therapeutic effects of this intervention.
The trial will be conducted at the Interdisciplinary Neuromodulation Service of the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo Medical School (IPq-HCFMUSP). Findings from this pilot study are intended to inform the design of future randomized, sham-controlled clinical trials and contribute to the expanding investigation of transcranial alternating current stimulation as a potential treatment modality in anxiety and sleep disorders.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
This study's planned enrollment of 30 is below the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Browse Generalized Anxiety Disorder studies →University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age between 18 and 65 years; Diagnosis of Generalized Anxiety Disorder (GAD) based on (DSM) criteria; Diagnosis of chronic primary insomnia; Hamilton Anxiety Rating Scale (HAM-A) score ≥15 at screening, indicating at least moderate anxiety severity; Score >5 on the Pittsburgh Sleep Quality Index (PSQI); Stable use of antidepressants (SSRI or SNRI) is allowed; Limited use of benzodiazepines (maximum of 10 mg/day diazepam equivalent).
Exclusion Criteria:
History of mania, hypomania, or bipolar disorder; to the use of transcranial stimulation; Active suicidal ideation or suicide attempt in the last 4 weeks; Refractoriness to 3 or more antidepressant treatments; Pregnancy; Other psychiatric diagnoses (e.g., schizophrenia, substance dependence, major depressive disorder); Severe medical or neurological conditions; Anxiety or insomnia secondary to other medical or psychiatric conditions (e.g., hypothyroidism, anemia).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 20 sessions of transcranial alternating current stimulation (tACS) over four weeks (five sessions per week). The stimulation will be delivered at 15 mA and 77.5 Hz using the Nexalin device, with electrodes placed at Fpz and mastoid areas.
Device: Transcranial Alternating Current Stimulation (tACS)
20 sessions of 40 minutes each, applied five times per week over four weeks, with a current of 15 mA at 77.5 Hz using the Nexalin device.
Change in Anxiety Severity Measured by the Hamilton Anxiety Rating Scale (HAM-A)
The Hamilton Anxiety Rating Scale (HAM-A) is a clinician-administered scale ranging from 0 to 56, with higher scores indicating greater anxiety severity. The outcome measure is the change in total HAM-A score from baseline to Week 4 and Week 8.
Time frame: Baseline, Week 4, Week 8
Change in Sleep Quality (Pittsburgh Sleep Quality Index - PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a self-reported questionnaire ranging from 0 to 21, with higher scores indicating worse sleep quality. The outcome measure is the change in total PSQI score from baseline to Week 4 and Week 8.
Time frame: Baseline, Week 4, Week 8
Change in Depressive Symptoms Measured by the Hamilton Depression Rating Scale (HAM-D)
The Hamilton Depression Rating Scale (HAM-D) ranges from 0 to 52, with higher scores indicating greater depressive symptom severity. The outcome measure is the change in total HAM-D score from baseline to Week 4 and Week 8.
Time frame: Baseline, Week 4, Week 8
Change in Global Clinical Status Measured by the Clinical Global Impression (CGI) Scale
The Clinical Global Impression (CGI) scale includes severity and improvement subscales. The CGI-Severity scale ranges from 1 to 7, with higher scores indicating greater illness severity. The outcome measure includes changes from baseline to Week 4 and Week 8.
Time frame: Baseline, Week 4, Week 8
Change in Quality of Life Measured by the WHOQOL-BREF
The World Health Organization Quality of Life - Brief Version (WHOQOL-BREF) is a self-reported questionnaire assessing quality of life across physical, psychological, social, and environmental domains. Scores range from 0 to 100, with higher scores indicating better quality of life. The outcome measure is the change in total score from baseline to Week 4 and Week 8.
Time frame: Baseline, Week 4, Week 8
Incidence of Treatment-Emergent Adverse Events
Number and nature of adverse events, including local discomfort, headache, skin irritation, or fatigue.
Time frame: Throughout the 8-week study period
Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in this article will be made available after deidentification, including study protocol and statistical analysis plan.
Supporting information: Study protocol
Time frame: Beginning 6 months following publication, for up to 2 years.
Access criteria: Qualified researchers whose proposals are approved by the principal investigator will be granted access to deidentified individual participant data. Requests must include a clear scientific rationale and plan for data use. Data will be shared through secure electronic transfer upon agreement with data use terms.
No publications or documents are linked to this record.
Ran from Jun 2025 to primary completion in Jan 2026, 7 months.
Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's 7 months is below that.
Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →